Welcome to our dedicated page for Nkarta news (Ticker: NKTX), a resource for investors and traders seeking the latest updates and insights on Nkarta stock.
Nkarta, Inc. (Nasdaq: NKTX) is a pioneering clinical-stage biotechnology company located in South San Francisco, California. Founded in 2015, Nkarta leverages proprietary natural killer (NK) cell expansion and engineering technologies to develop next-generation immunotherapies for the treatment of cancer and autoimmune diseases. The company’s mission is to harness the innate power of NK cells, which are the body's first line of defense, to create treatments that are more potent, better tolerated, and readily available to a broad patient population.
The core focus of Nkarta lies in its two lead candidates, NKX101 and NKX019. NKX101 is an off-the-shelf immunotherapy that targets NKG2D ligands on tumor cells, using engineered NK cells derived from healthy donors. This candidate shows promising results in treating acute myeloid leukemia (AML), with complete responses observed in high-risk patients. NKX019 targets CD19, a biomarker for B cell malignancies and autoimmune diseases such as lupus nephritis. This candidate has been designed to provide enhanced tumor cell targeting and greater persistence and activity.
Nkata's technological platform combines NK cell expansion and cryopreservation with advanced cell engineering techniques, including CRISPR-based genome engineering. This ensures a robust supply of NK cells and enables precise modification for enhanced therapeutic effectiveness. The company's cell therapies aim to be accessible for broad outpatient treatment, offering off-the-shelf solutions that minimize patient burden and reduce treatment delays.
Recent milestones include the clearance of an Investigational New Drug (IND) application by the U.S. FDA to evaluate NKX019 for lupus nephritis, expansion of their pipeline into autoimmune diseases, and strategic financial moves to extend their cash runway into 2026. Nkarta continues to provide updates on its clinical programs and looks forward to presenting additional data throughout 2024.
The company's financial backing comes from prominent investors such as SR One, NEA, and Novo Ventures, which underscores confidence in Nkarta's potential to revolutionize cell therapy. With a commitment to rigorous clinical development and strategic resource allocation, Nkarta is well-positioned to advance its innovative cell therapy candidates and deliver transformative treatments to patients in need.
Nkarta, Inc. (Nasdaq: NKTX) presented groundbreaking preclinical data at the 2023 AACR Annual Meeting, highlighting the enhanced efficacy of engineered natural killer (NK) cell therapies. The studies showcased the combination of NKX101, targeting the NKG2D receptor, with the monoclonal antibody cetuximab, leading to significant improvements in cancer cell killing in vitro. Additionally, researchers demonstrated that ADAM17 gene knockout in NK or CAR NK cells enhances antibody-dependent cellular cytotoxicity (ADCC) and overall anti-tumor activity. These findings emphasize the potential of NKX101 and ADAM17 KO therapies in treating solid tumors, marking a critical step toward clinical application. The studies support further exploration of NK cell therapies combined with therapeutic antibodies for improved anti-tumor treatments.
Nkarta, a biopharmaceutical company focused on engineered natural killer (NK) cell therapies for cancer, announced its participation in two investor conferences:
- 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 3:00 p.m. ET - featuring a fireside chat.
- Canaccord Genuity Horizons in Oncology Virtual Conference on April 20, 2023, at 3:00 p.m. ET - featuring a panel discussion.
Webcasts of these events will be available on the Investors section of Nkarta's website, with replays archived for approximately 90 days. Nkarta specializes in off-the-shelf NK cell therapies aimed at providing broad access and deep anti-tumor activity in outpatient settings, utilizing advanced cell engineering technologies.
Nkarta, Inc. (NASDAQ: NKTX) announced that its CFO, Nadir Mahmood, PhD, has resigned to become CEO of another biotech firm, remaining until June 30, 2023, to ensure a smooth transition. Nkarta is on schedule to release updated results from its NKX101 clinical trial in Q2 2023 and is initiating external searches for a new CFO. This transition follows Mahmood's five years at Nkarta, highlighted by his contributions to advancing NK cell therapies aimed at treating cancer. Nkarta remains focused on developing its pipeline and maintaining progress in clinical trials.
Nkarta, Inc. (Nasdaq: NKTX) reported its financial results for Q4 and the full year 2022, highlighting a net loss of $113.8 million or $2.61 per share. As of December 31, 2022, the company had cash and equivalents of $354.9 million, projected to fund operations into 2025. Nkarta is advancing its NKX101 and NKX019 therapies, with clinical updates expected in 2023. NKX101 showed a 60% complete response rate in r/r AML patients, while NKX019 demonstrated a 70% complete response in relapsed/refractory B-cell malignancies. Both therapies appear well-tolerated, with no significant toxicity reported.
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company focused on engineered natural killer (NK) cell therapies for cancer, announced its participation in three notable investor conferences. The events include the SVB Securities Global Biopharma Conference on February 14, 2023, where a fireside chat is slated for 3:40 p.m. ET; the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, with timing to be determined; and the Cowen 43rd Annual Health Care Conference on March 8, 2023, featuring an industry panel discussion at 2:10 p.m. ET. Webcasts of the events will be accessible on Nkarta’s website, with replays available for 90 days.
Nkarta, Inc. (Nasdaq: NKTX) has announced the promotion of Dr. David R. Shook to Chief Medical Officer. Dr. Shook has significant expertise in NK cell therapy and has been with Nkarta since 2020, previously serving as Vice President of Clinical Development. His leadership is expected to enhance the company's clinical strategy and development of cell therapies. Nkarta focuses on engineered NK cell therapies to treat cancer, aiming for broad access and impactful patient treatment. Forward-looking statements caution on risks and uncertainties affecting Nkarta's clinical outcomes and financial position.
Nkarta, Inc. (NASDAQ: NKTX) reported promising results from its Phase 1 dose escalation study of NKX019, an engineered NK cell therapy for relapsed or refractory non-Hodgkin lymphoma (NHL). Notably, 7 out of 10 patients treated at higher doses achieved a complete response (70% CR rate). Five complete responses were achieved after a single treatment cycle, with durable responses lasting over six months in several cases. The therapy demonstrated a favorable safety profile, with no significant toxicities observed. Nkarta is expanding the study with combination therapies and plans to share further updates in 2023.
Nkarta, Inc. (Nasdaq: NKTX) announces a conference call on December 5, 2022, at 8:00 a.m. ET to discuss updated clinical data from its ongoing Phase 1 trial of NKX019, a CD19-directed CAR NK cell therapy. NKX019 is designed to treat relapsed/refractory B cell malignancies and is being assessed for safety and anti-tumor activity as both monotherapy and combination therapy. The call will provide vital insights into the therapy's progress, and accompanying slides will be accessible on Nkarta's website.
Nkarta, a clinical-stage biopharmaceutical company, reported significant clinical advancements in its NKX101 and NKX019 programs. As of Sept 30, 2022, cash reserves totaled $395.1 million. The company has opened dose expansion cohorts for NKX019 and anticipates clinical updates for both NKX019 and NKX101 in 2022 and 2023, respectively. During Q3 2022, R&D expenses were $23.4 million, contributing to a net loss of $28.3 million, or $0.58 per share. Despite losses, Nkarta expects sufficient cash to sustain operations into 2025.
Nkarta, Inc. (Nasdaq: NKTX) presented two preclinical data abstracts at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting. Notably, NKX019, a CAR NK cell, demonstrated improved anti-tumor activity when combined with CD20 antibodies like rituximab. Additionally, the company's proprietary manufacturing platform achieved over a billion-fold expansion of NK cells while preserving potency, enabling potential commercial-scale therapy production from a single donor. Nkarta aims to enhance cancer treatment accessibility through engineered NK cell therapies.
FAQ
What is the current stock price of Nkarta (NKTX)?
What is the market cap of Nkarta (NKTX)?
What does Nkarta, Inc. specialize in?
Where is Nkarta, Inc. located?
What are Nkarta's lead therapy candidates?
How does Nkarta source its NK cells?
What are the recent achievements of Nkarta?
Who are some of Nkarta's investors?
How does Nkarta ensure its therapies are readily available?
What is the focus of Nkarta's NKX019 therapy?
What technological platforms does Nkarta use?
What future updates is Nkarta expected to provide?
